Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
One Percent Rule Checklist For Safer Forex Trading Risk 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
VANCOUVER, British Columbia, April 19, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization process, the Company’s request to voluntarily delist its common shares on the Toronto Stock Exchange ("TSX") at the close of markets on May 3, 2017 has been granted. The Company’s shares will continue to trade on the NASDAQ Global Select Market under the symbol “NVLN”.
The Company believes that the low trading volume of its shares on the TSX over a sustained period no longer justifies the financial and administrative costs associated with maintaining a dual listing. Canadian shareholders will be able to continue to trade the Company’s shares on the NASDAQ exchange through their brokers who have U.S. registered broker-dealer affiliates.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
